Abstract
The preferential accumulation of NeuGcGm3 in a variety of malignant tumors, compared with healthy tissues, made this molecule as an attractive target for cancer immunotherapy. 14F7 monoclonal antibody is a highly specific IgG1 against NeuGcGM3 gangliosid. The immunohistochemical detection of NeuGcGM3 allows the potential selection of patients for specific therapy with anti-idiotype racotumomab cancer vaccine. Racotumomab is an anti-idiotype vaccine, mimics this ganglioside and triggers an immune response.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
